Evidence map›Paper›PMID 31181662›Full record

ArticlePharmaceutics2019

Nasal Administration and Plasma Pharmacokinetics of Parathyroid Hormone Peptide PTH 1-34 for the Treatment of Osteoporosis.

Richard G Pearson, Tahir Masud, Elaine Blackshaw, Andrew Naylor, Michael Hinchcliffe, Kirk Jeffery, Faron Jordan, Anjumn Shabir-Ahmed, Gareth King, Andrew L Lewis and 2 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Development andDrug delivery · 2021
    Article
  5. Article
  6. Article
  7. Role of Ca²⁺ in Inhibiting Ischemia-Induced Apoptosis of Parathyroid Gland Cells in New Zealand White Rabbits.Medical science monitor : international medical journal of experimental and clinical research · 2020
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Richard G PearsonDivision of Rheumatology, Orthopaedics and Dermatology, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. richard.pearson@nottingham.ac.uk.
Tahir MasudNottingham University Hospitals NHS Trust, Queen's Med Centre, University of Nottingham, Nottingham NG7 2UH, UK. tahir.masud@nuh.nhs.uk.
Elaine BlackshawRadiological Sciences, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. elaine.blackshaw@nottingham.ac.uk.
Andrew NaylorCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. anaylor@upperton.com.
Michael HinchcliffeParacelsis Ltd., BioCity Nottingham, Pennyfoot Street, Nottingham NG1 1GF, UK. mh@paracelsis.com.
Kirk JefferyCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. kjeffery@upperton.com.
Faron JordanCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. faron.jordan@hotmail.co.uk.
Anjumn Shabir-AhmedCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. anjumnshabir@yahoo.com.
Gareth KingCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. gareth.king@catapult-ventures.com.
Andrew L LewisCritical Pharmaceuticals Ltd., Bio City, Pennyfoot Street, Nottingham NG1 1GF, UK. andrew.lewis@quotientsciences.com.
Lisbeth IllumIdentity, 19 Cavendish Crescent North, The Park, Nottingham NG71BA, UK. lisbeth.illum@illumdavis.com.
Alan C PerkinsRadiological Sciences, School of Medicine, Queen's Medical Centre, University of Nottingham, Nottingham NG7 2UH, UK. alan.perkins@nottingham.ac.uk.ORCID 0000-0002-1054-8200
Critical Pharmaceuticals (United Kingdom) · GBUniversity of Nottingham · GBNottingham University Hospitals NHS Trust · GB

Funding

Engineering and Physical Sciences Research Council EP/K502364/1Engineering and Physical Sciences Research Council EP/K503800/1Technology Strategy Board 17223-124195
6 · The paper itself

Abstract

Nasal delivery of large peptides such as parathyroid 1-34 (PTH 1-34) can benefit from a permeation enhancer to promote absorption across the nasal mucosa into the bloodstream. Previously, we have published an encouraging bioavailability (78%), relative to subcutaneous injection in a small animal preclinical model, for a liquid nasal spray formulation containing the permeation enhancer polyethylene glycol (15)-hydroxystearate (Solutol

Indexed as

clinical trialmannasal deliveryosteoporosispharmacokineticspreclinicalPTH 1-34sheepteriparatide

Identifiers

PMID31181662
PMCPMC6631119
OpenAlexW2948757546

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.